Search
Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … use alongside solifenacin in refractory cases.
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexTixocortol
go.drugbank.com/drugs/DB09091ApprovedWithdrawnTixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. … It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and toxicity.[L1078]
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. … [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Acipimox is a niacin derivative used as a hypolipidemic agent.
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalor/and that fill an unmet medical need based on a surrogate endpoint. … [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTenecteplase
go.drugbank.com/drugs/DB00031ApprovedInvestigational296-299 in the protease domain. … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids
SGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Categories: Compounds used in a research, industrial, or household settingSynonyms: (3-Aminopropyl)(n-butyl)phosphinic acidTiclopidine
go.drugbank.com/drugs/DB00208ApprovedIt is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.
Products: TICLOPIDIN AL 250Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedAlpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]